On March 22, 2022 Mission Therapeutics ("Mission"), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), reported that Dr Paul Wallace, Chief Business Officer, will attend the sixteenth annual BIO-Europe Spring conference (28-31 March) (Press release, Mission Therapeutics, MAR 22, 2022, View Source [SID1234610561]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BIO-Europe Spring is one of the most international gatherings in the biopharma industry, bringing together the life science community for global dealmaking. Dr Paul Wallace will join participants from other leading companies in the sector, attending meetings, panel discussions, and showcases, and is available for one-to-one meetings. The event is being held virtually.